| 发明名称 |
COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE |
| 摘要 |
The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. |
| 申请公布号 |
US2015079073(A1) |
申请公布日期 |
2015.03.19 |
| 申请号 |
US201414251308 |
申请日期 |
2014.04.11 |
| 申请人 |
Roche Glycart AG |
发明人 |
DREYLING MARTIN;HEINRICH DANIEL ALEXANDER;HERTING FRANK;KLEIN CHRISTIAN |
| 分类号 |
A61K39/395;A61K45/06;A61K31/136;A61K31/7076;A61K31/661 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. Use of an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, for the manufacture of a medicament for the treatment of cancer in combination with fludarabine and/or mitoxantrone. |
| 地址 |
Schlieren CH |
